Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492845 | 1.00 | MMP2 (0.33) | MMP2ANPEPHCRTR2DPP4 | |
| SCHEMBL24375001 | 0.88 | ATM (0.33) | HCRTR2DPP4 | |
| SCHEMBL18513346 | 0.88 | ATM (0.33) | HCRTR2DPP4 | |
| SCHEMBL12211119 | 0.85 | ADORA2A (0.37) | MMP2ANPEP | |
| SCHEMBL20209391 | 0.85 | ADORA2A (0.37) | MMP2ANPEP | |
| SCHEMBL23710651 | 0.85 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL24119964 | 0.85 | CHRNB2 (0.32) | DPP4 | |
| SCHEMBL18513313 | 0.85 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL22372628 | 0.84 | — | — | |
| SCHEMBL24098413 | 0.84 | HCRTR2 (0.31) | MMP2ANPEPHCRTR2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193284-A1 | TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-06-22 | — | — | US | disclosed |
| US-20220389419-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2021030522-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389419-A1 | MODIFIED OLIGONUCLEOTIDES | EIF2AK2, RNASE1, SNRPE | MMP2 3953/4885ANPEP 3338/4885HCRTR2 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.